PTC Therapeutics acquires Fabry disease gene therapy from Sangamo

September 21, 2026 4:30 PM

PTC Therapeutics, Inc. (NASDAQ: PTCT) has completed its acquisition of ST-920, a one-time administered AAV gene therapy for Fabry disease ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found